Sam Brusco, Associate Editor04.19.22
Foot and ankle orthopedic firm Paragon 28 has launched the R3ACT stabilization system, a solution for multi-stage soft tissue healing after an acute or chronic syndesmotic ankle injury.
“Since the inception of Paragon 28, the development of a syndesmotic stabilization system for ankle injuries has been a top priority for us,” Paragon 28 CEO Albert DaCosta told the press. “We believe this unique and proprietary product addresses the complexities of this indication and mimics not only the dynamic environment, but also transitions the function of stabilization to best match the healing phases of the soft tissues. Approximately 20% of all ankle injuries require implants for soft tissue healing. As a result, we believe the R3ACT Stabilization System will be a nice complement to our entire ankle fracture portfolio.”
The company posted full-year 2021 sales of $147.5 million, which represents a 33% gain over the previous year. The company predicts this year’s revenue to be in the range of $167-171 million.
“Since the inception of Paragon 28, the development of a syndesmotic stabilization system for ankle injuries has been a top priority for us,” Paragon 28 CEO Albert DaCosta told the press. “We believe this unique and proprietary product addresses the complexities of this indication and mimics not only the dynamic environment, but also transitions the function of stabilization to best match the healing phases of the soft tissues. Approximately 20% of all ankle injuries require implants for soft tissue healing. As a result, we believe the R3ACT Stabilization System will be a nice complement to our entire ankle fracture portfolio.”
The company posted full-year 2021 sales of $147.5 million, which represents a 33% gain over the previous year. The company predicts this year’s revenue to be in the range of $167-171 million.